A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 502 participants.
Also called NCT05646381
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 502 participants
- Sponsor
- Registry
-
NCT05646381
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05646381. Randomized; double masking; primary purpose treatment. Start 2024-03-07 (actual); primary completion 2030-03-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- Condition
- Aortic Stenosis
- Intervention (Drug)
- Pelacarsen (TQJ230) 80mg
- Intervention (Drug)
- Matching placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05646381- Content hash
f86e14f725abf84e290286f09eeed55894c0ab2219309fbdede67863691ea199